Topics

A subset of #cancer patients treated with the newly approved TRK inhibitor, larotrectinib, develop off-target resistance through acquisition of MAPK-activating genomic alterations #precisiononcology @sloan_kettering | http://go.nature.com/2YuJ5Nb pic.tw

10:00 EDT 11 Sep 2019 | Nature Publishing

A subset of patients treated with the newly approved TRK inhibitor, larotrectinib, develop off-target resistance through acquisition of MAPK-activating genomic alterations | http://go.nature.com/2YuJ5Nb 

Original Article: A subset of #cancer patients treated with the newly approved TRK inhibitor, larotrectinib, develop off-target resistance through acquisition of MAPK-activating genomic alterations #precisiononcology @sloan_kettering | http://go.nature.com/2YuJ5Nb pic.tw

NEXT ARTICLE

More From BioPortfolio on "A subset of #cancer patients treated with the newly approved TRK inhibitor, larotrectinib, develop off-target resistance through acquisition of MAPK-activating genomic alterations #precisiononcology @sloan_kettering | http://go.nature.com/2YuJ5Nb pic.tw"

Quick Search

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...